S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
Log in
OTCMKTS:ZYXI

Zynex Stock Forecast, Price & News

$13.77
+0.18 (+1.32 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.31
Now: $13.77
$13.89
50-Day Range
$13.59
MA: $16.32
$19.73
52-Week Range
$7.51
Now: $13.77
$29.73
Volume506,076 shs
Average Volume815,199 shs
Market Capitalization$477.90 million
P/E Ratio62.59
Dividend YieldN/A
Beta1.05
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Read More
Zynex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
CUSIPN/A
Phone303-703-4906
Employees283

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.43 million
Cash Flow$0.77 per share
Book Value$0.15 per share

Profitability

Net Income$7.36 million

Miscellaneous

Market Cap$477.90 million
Next Earnings Date10/27/2020 (Estimated)
OptionableNot Optionable
$13.77
+0.18 (+1.32 %)
(As of 10/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zynex (OTCMKTS:ZYXI) Frequently Asked Questions

How has Zynex's stock been impacted by COVID-19 (Coronavirus)?

Zynex's stock was trading at $11.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZYXI shares have increased by 24.2% and is now trading at $13.77.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zynex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zynex
.

When is Zynex's next earnings date?

Zynex is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Zynex
.

How were Zynex's earnings last quarter?

Zynex, Inc. (OTCMKTS:ZYXI) issued its earnings results on Tuesday, July, 28th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.00. The business earned $19.26 million during the quarter, compared to analyst estimates of $19.12 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%.
View Zynex's earnings history
.

What guidance has Zynex issued on next quarter's earnings?

Zynex issued an update on its third quarter 2020 Pre-Market earnings guidance on Monday, October, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20.5 million, compared to the consensus revenue estimate of $22.72 million.

What price target have analysts set for ZYXI?

4 analysts have issued 12 month target prices for Zynex's shares. Their forecasts range from $22.50 to $30.00. On average, they anticipate Zynex's stock price to reach $26.38 in the next year. This suggests a possible upside of 91.5% from the stock's current price.
View analysts' price targets for Zynex
.

Who are some of Zynex's key competitors?

What other stocks do shareholders of Zynex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Advanced Micro Devices (AMD), Pfizer (PFE), Farfetch (FTCH), K12 (LRN), AbbVie (ABBV), Activision Blizzard (ATVI), Big Lots (BIG), Chromadex (CDXC), Chegg (CHGG) and Dell (DELL).

Who are Zynex's key executives?

Zynex's management team includes the following people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 61, Pay $523.04k)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 48, Pay $352.86k)
  • Mr. Joseph Papandrea, Chief Operating Officer (Age 47, Pay $272.31k)
  • Ms. Chelle Van Burkleo, VP of Sales
  • Mr. Joachim Sandgaard, Information Systems Mang.

What is Zynex's stock symbol?

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Who are Zynex's major shareholders?

Zynex's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cadence Capital Management LLC (0.09%), Juncture Wealth Strategies LLC (0.08%), State of Alaska Department of Revenue (0.05%), Newman Dignan & Sheerar Inc. (0.04%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard.
View institutional ownership trends for Zynex
.

Which major investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC.
View insider buying and selling activity for Zynex
.

Which major investors are buying Zynex stock?

ZYXI stock was bought by a variety of institutional investors in the last quarter, including Juncture Wealth Strategies LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, and Newman Dignan & Sheerar Inc..
View insider buying and selling activity for Zynex
.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $13.77.

How big of a company is Zynex?

Zynex has a market capitalization of $477.90 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. Zynex employs 283 workers across the globe.

What is Zynex's official website?

The official website for Zynex is www.zynexmed.com.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.